Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11950523 | 0.86 | CA2 (0.48) | CA2TAAR1PKMALOX15HSD17B1 | |
| SCHEMBL12806397 | 0.85 | CA2 (0.44) | CA2PKMALOX15GAAPTGS2 | |
| SCHEMBL20286678 | 0.84 | CA2 (0.63) | CA2TAAR1PKMALOX15GAA | |
| SCHEMBL18264884 | 0.81 | PKM (0.46) | CA2TAAR1PKMALOX15GAA | |
| SCHEMBL9886085 | 0.81 | GABRA1 (0.55) | TAAR1ALOX5GABRA1GABRB2ALDH1A1 | |
| SCHEMBL2278377 | 0.81 | TAAR1 (0.52) | CA2TAAR1PKMALOX15GAA | |
| SCHEMBL16372569 | 0.80 | DPP4 (0.44) | CA2PKMALOX15GAAMEN1 | |
| SCHEMBL7632612 | 0.79 | CA2 (0.68) | CA2GAAALDH1A1KDM4EATM | |
| SCHEMBL24021272 | 0.79 | ALDH1A1 (0.49) | CA2TAAR1PKMALOX15ALOX5 | |
| Hydrochloric Acid SCHEMBL6768219 | 0.79 | TAAR1 (0.50) | CA2TAAR1PKMALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505878-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | CA2 90/4885TAAR1 4366/4885PKM 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.